Truist raised the firm’s price target on AbbVie (ABBV) to $217 from $211 and keeps a Buy rating on the shares after its Q4 results. The company’s FY24 results exceeded the management’s recent guidance as AbbVie continues to deliver strong growth into the longer-term, and the firm sees a clear growth trajectory into 2029, the analyst tells investors in a research note.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV: